Global Antineoplastic Agent
Market Report
2024
The global Antineoplastic Agent Market size will be USD 128474.2 million in 2024. The increasing demand for chemotherapeutic agents and biological/immunotherapeutic agents is expected to boost sales to USD 275258.02 million by 2031, with a Compound Annual Growth Rate (CAGR) of 11.50% from 2024 to 2031.
The base year for the calculation is 2023 and 2019 to 2023 will be historical period. The year 2024 will be estimated one while the forecasted data will be from year 2025 to 2031. When we deliver the report that time we updated report data till the purchase date.
PDF Access: Password protected PDF file, Excel File Access: Quantitative data, PPT Report Access: For the presentation purpose, Cloud Access: Secure Company Account Access.
Share your contact details to receive free updated sample copy/pages of the recently published edition of Antineoplastic Agent Market Report 2024.
According to Cognitive Market Research, the global Antineoplastic Agent market size will be USD 128474.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 11.50% from 2024 to 2031.
Base Year | 2023 |
Historical Data Time Period | 2019-2023 |
Forecast Period | 2024-2031 |
Global Antineoplastic Agent Market Sales Revenue 2024 | $ 128474 Million |
Global Antineoplastic Agent Market Compound Annual Growth Rate (CAGR) for 2024 to 2031 | 11.5% |
Market Drivers:
| |
Market Restrains:
| |
Market Trends:
|
Market Split by Product |
|
Market Split by Type of cancer |
|
Market Split by End User |
|
List of Competitors |
|
Regional Analysis |
|
Country Analysis |
|
Key Qualitative Information Covered |
|
Report scope is customizable as we have a huge database of Antineoplastic Agent industry. We can deliver an exclusive report Edition/Consultation as per your data requirements. Request for your Free Sample Pages.
Antineoplastic Agent Market is Segmented as below. Particular segment of your interest can be provided without any additional cost. Download the Sample Pages!
The market for antineoplastic agents, which includes many drugs used in the treatment of cancer, is expanding rapidly due to a number of factors. Traditional chemotherapy, targeted therapy, hormone therapy, immunotherapy, and more recent techniques like CAR-T cell therapy are some of these medicines. The need for efficient cancer treatments is growing as the number of people affected by cancer worldwide rises as a result of aging populations, changing lifestyles, and environmental factors. In addition, because the risk of cancer grows with age, the aging of the world population contributes to the increased prevalence of cancer. One major element fueling the demand for antineoplastic drugs is this demographic shift. Antineoplastic agent development and accessibility are being supported by increased government financing for cancer research and activities targeted at enhancing the infrastructure for cancer care.
For instance, According to WHO data from 2020, there was a maximum number of patients with breast cancer (2.26 million) out of total cancer cases. Since then, the figures have increased, indicating a sizable market for pharmaceutical medicines that prevent neoplastic growth. (Source:https://www.who.int/news-room/fact-sheets/detail/cancer)
The market for antineoplastic agents is growing, and one of the main reasons for this is the rising incidence of cancer. The need for efficient cancer treatments is growing as the number of people affected by cancer worldwide rises due to aging populations, changing lifestyles, and environmental factors. Antineoplastic drugs, such as immunotherapies, targeted treatments, and chemotherapies, are crucial for the management of a variety of malignancies. Increased use of current medicines, as well as the creation of new, more potent medications, are both fueled by this increased occurrence. As a result, to address the increasing demand for sophisticated cancer treatments, pharmaceutical companies and healthcare providers are making significant investments in research & development. This will ultimately drive the market's growth and give better outcomes for patients across the globe.
The antineoplastic agent industry is growing at a high rate because of advancements in drug development. Biotechnology advances, including immunotherapies, targeted medicines, and customized medicine, are revolutionizing cancer treatment. By addressing the unique genetic and molecular profiles of individual cancers, these developments pave the way for the development of more potent and less hazardous treatments. Next-generation sequencing and CRISPR gene editing are two cutting-edge technologies that are speeding up the search for and creation of new antineoplastic drugs. Artificial intelligence is also helping to expedite the process of finding new drug candidates and improve clinical trial procedures in the field of drug discovery. The efficacy and safety of cancer treatments are being improved by these developments, which are growing the market and increasing patient outcomes.
The market for antineoplastic agents is severely constrained by the high cost of treatment. A significant number of patients, particularly those in low- and middle-income nations, are unable to afford the high costs associated with many sophisticated cancer therapies, such as immunotherapies and targeted therapies. In addition to having an impact on patients, this financial hardship also puts pressure on insurance companies and healthcare systems, which can result in problems with reimbursement and insufficient coverage. Expensive therapies may discourage patients from following their doctors' orders, which could lead to less-than-ideal results. Furthermore, these medicines' high costs can impede market expansion and prevent wider use. In order to guarantee greater access to cancer treatments that can save lives and achieve fair healthcare outcomes, it is imperative to address the cost of antineoplastic drugs.
The market for antineoplastic agents was severely damaged by the COVID-19 pandemic, which also caused supply chain disruptions, postponed clinical trials, and delayed medicinal approvals. The prioritization of COVID-19 care by healthcare systems resulted in treatment delays for numerous cancer patients, potentially exacerbating the condition and influencing drug demand. Economic hardships brought on by the epidemic also decreased healthcare spending and restricted patient access to pricey cancer treatments. On the other hand, it expedited the uptake of digital health and telemedicine, enabling remote patient consultations and monitoring. Additionally, several quick developments in medication research were sparked by the heightened focus on healthcare advances and emergency regulatory measures. COVID-19 presented difficulties, but it also brought attention to the necessity of robust healthcare systems and cutting-edge methods for managing and treating cancer.
We have various report editions of Antineoplastic Agent Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.
The competitive landscape of the Antineoplastic Agent market is distinguished by a wide variety of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established anticancer drug manufacturers, specialized Antineoplastic Agent companies, and emerging start-ups aiming to disrupt the market with innovative solutions.
October 2022: Amgen acquired ChemoCentryx, Inc. ChemoCentryx, Inc. is a biopharmaceutical company that specializes in oral medications to treat cancer, inflammatory disorders, and autoimmune diseases. (Source:https://www.amgen.com/newsroom/press-releases/2022/10/amgen-successfully-completes-acquisition-of-chemocentryx) March 2021: ImmunityBio, Inc. and NantKwest, Inc. combined to establish a leading late-stage cell therapy and immunotherapy business with an emphasis on infectious diseases and cancer. (Source:https://immunitybio.com/immunitybio-and-nantkwest-complete-merger/)Top Companies Market Share in Antineoplastic Agent Industry: (In no particular order of Rank)
If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.
Global Antineoplastic Agent Market Report 2024 Edition talks about crucial market insights with the help of segments and sub-segments analysis. In this section, we reveal an in-depth analysis of the key factors influencing Antineoplastic Agent Industry growth. Antineoplastic Agent market has been segmented with the help of its Product, Type of cancer End User, and others. Antineoplastic Agent market analysis helps to understand key industry segments, and their global, regional, and country-level insights. Furthermore, this analysis also provides information pertaining to segments that are going to be most lucrative in the near future and their expected growth rate and future market opportunities. The report also provides detailed insights into factors responsible for the positive or negative growth of each industry segment.
According to Cognitive Market Research, Chemotherapeutic Agents are the dominating category. Chemotherapeutic drugs, a significant market sector for antineoplastic medicines, are extensively employed in the treatment of diverse cancer types by specifically targeting cells that divide quickly. These medications, which include alkylating agents, antimetabolites, and natural products, cause cancer cells to die by interfering with DNA replication and cell division. Chemotherapy plays a crucial part in comprehensive cancer care since it is frequently used in conjunction with radiation therapy, surgery, and other treatments to improve treatment efficacy, manage advanced tumors, and lower the risk of cancer recurrence.
Biological/immunotherapeutic Agents is the fastest-growing category in the Antineoplastic Agent market. This is due to the use of the body's immune system to combat cancer, and biological and immunotherapeutic medicines play a crucial role in the antineoplastic agent industry. These drugs, which target certain cancer cell markers and boost the immune system, include checkpoint inhibitors, CAR-T cell treatments, and monoclonal antibodies. When compared to conventional treatments, these therapies offer better specificity and fewer adverse effects for treating a variety of tumors, including lymphomas, lung cancer, and melanoma. To boost effectiveness and enhance patient outcomes, immunotherapies are frequently used in conjunction with other medications.
The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Antineoplastic Agent Industry. Request a Free Sample PDF!
According to Cognitive Market Research, the dominating category is Breast Cancer. Due to the high incidence rates and improvements in therapeutic choices, there is a large demand for breast cancer treatments in the antineoplastic agent market. With better survival rates and customized treatment regimens, targeted medicines such as CDK4/6 inhibitors, hormone therapy, and HER2 inhibitors are essential for the management of breast cancer. The range of available treatments is increasing due to ongoing research and the introduction of novel drugs, such as immunotherapies. The need for efficient anti-cancer drugs is also fueled by greater access to healthcare, early detection initiatives, and more public awareness.
The fastest-growing category in the Antineoplastic Agent market is Bladder Cancer. Because bladder cancer incidence rates are on the rise and effective treatments are needed, there is a developing market for antineoplastic medicines. Checkpoint inhibitors are examples of immunotherapies that are being utilized more and more because they provide notable improvements over conventional chemotherapies. Patients now have more alternatives thanks to advancements in targeted therapy and the creation of innovative medicines, especially those with advanced or metastatic disease. The need for sophisticated antineoplastic medicines in the treatment of bladder cancer is being further driven by improved diagnostic methods and more awareness, which are supporting the disease's diagnosis and treatment earlier.
The above Graph is for representation purposes only. This chart does not depict actual Market share. Please purchase the Antineoplastic Agent market report 2024 Edition by contacting our team.
According to Cognitive Market Research, the dominating category is Hospitals. Hospitals are important end users in the antineoplastic agent market since they are the main facilities for patient care, cancer diagnosis, and treatment. In addition to administering immunotherapies, targeted treatments, and chemotherapies, they offer full-service oncology care. Hospitals enable access to cutting-edge therapies and individualized care plans by facilitating clinical trials. Their interdisciplinary staff and cutting-edge infrastructure guarantee efficient care for cancer patients. Hospitals' demand for a wide variety of antineoplastic medicines is supported by the increased prevalence of cancer and the need for specialized care, highlighting their essential function in handling the treatment of cancer.
The fastest-growing category in the Antineoplastic Agent market is Cancer Rehabilitation Centers. Cancer rehabilitation facilities, which concentrate on the recovery of cancer patients after treatment and the enhancement of their quality of life, are important end-users in the antineoplastic agent market. These centers offer specialist care that frequently calls for ongoing antineoplastic medication use in order to control residual disease and avoid recurrence. This care includes physical therapy, pain management, and psychological support. Rehab facilities use a holistic approach that incorporates cutting-edge cancer therapies into individualized treatment plans. There is a growing need for antineoplastic drugs at these hospitals due to the need for complete post-treatment care to be recognized.
According to Cognitive Market Research, North America led the market in 2024, accounting for almost 40% of worldwide sales. Because of its sophisticated healthcare system, large investments in cancer research, and high cancer incidence, North America is expected to lead the antineoplastic agent market. The market is further propelled forward by the region's strong emphasis on innovation and early adoption of cutting-edge treatments like immunotherapy and customized medicine. Government funds and efforts support cancer research and development, and a strong regulatory system ensures the prompt approval of novel medicines. Furthermore, North America's dominant position in the worldwide antineoplastic agent market is a result of its high healthcare costs and easy access to state-of-the-art medical technologies.
Asia-Pacific stands out as the fastest-growing region in the Antineoplastic Agent market. The market for Antineoplastic agents is expected to increase significantly thanks to Asia Pacific's potential. More advanced cancer therapies are becoming accessible in the region due to factors like rising cancer prevalence, better healthcare infrastructure, and higher disposable incomes. Prioritizing healthcare reforms and funding oncology research and development are top priorities for governments in nations like China, India, and Japan. Furthermore, market expansion is being driven by the increasing use of innovative therapies, such as targeted treatments and immunotherapy. Asia Pacific offers pharmaceutical businesses looking to address the changing cancer treatment environment in the region a significant development opportunity due to its vast population base and rising healthcare costs.
The current report Scope analyzes Antineoplastic Agent Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com
The above graph is for illustrative purposes only. To learn more about geographical trends request the free sample pages. Contact US!
According to Cognitive Market Research, the global Antineoplastic Agent market size was estimated at USD 128474.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 51389.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.
According to Cognitive Market Research, the global Antineoplastic Agent market size was estimated at USD 128474.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 38542.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031
According to Cognitive Market Research, the global Antineoplastic Agent market size was estimated at USD 128474.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 29549.07 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.
According to Cognitive Market Research, the global Antineoplastic Agent market size was estimated at USD 128474.2 Million, out of which Latin America market of more than 5% of the global revenue with a market size of USD 6423.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031.
According to Cognitive Market Research, the global Antineoplastic Agent market size was estimated at USD 128474.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 2569.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031.
Senior Research Associate at Cognitive Market Research
Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.
I am a dedicated and detail-oriented research analyst, committed to unraveling the stories hidden within data. With a solid foundation in market research & analysis, I thrive in the dynamic realm of research, where every dataset presents an opportunity for discovery. My passion lies in utilizing innovative approaches to distill complex information into strategic insights that empower organizations to make informed decisions.
I am committed to continuous professional development, regularly participating in workshops, attending conferences, and staying attuned to emerging trends in research methodologies to maintain the highest standards in my work. I played a vital role in conducting market research and competitive analysis. I have a proven track record of synthesizing diverse datasets, employing statistical models, and presenting comprehensive insights. My collaborative approach with cross-functional teams facilitated effective communication of findings, fostering a culture of data-driven decision-making within the organization.
Conclusion
Table of Content differs accordign to the user License selction. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section's Or chapter's from the report. Specific section's of report can be ordered at a discounted price. If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Product | Chemotherapeutic Agents, Biological/immunotherapeutic Agents, Hormonal Agents, Personalized Medicines, Alkylating and Alkylating-like Agents, Miscellaneous Agents |
Type of cancer | Breast Cancer, Bladder Cancer, Lung Cancer, Leukemia, Cervical Cancer, Gynecological Cancer, Other Cancer Types |
End User | Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers |
List of Competitors | AbbVie, Baekdu Mountain Pharmaceutical, Baida Pharmaceutical, Abraxis, AstraZeneca, Biogen Idec, BMS, Jiangsu Hengrui Pharmaceutical, Johnson and Johnson, Jiangsu Haosen Pharmaceutical Group, Liaoning Novino Pharmaceutical, Lilly, Celgene, Eisai, Teva, Maanshan Fengyuan Pharmaceutical, Meiluo Pharmaceutical, Novartis, Pfizer, Shandong New Era Pharmaceutical, Qilu Pharmaceutical, Shandong Luoxin Pharmaceutical Group, Sinopharm, Tesaro (GSK), Zhejiang Kanglaite Pharmaceutical, Wto-Day Order Pharmaceutical, Zhejiang Yatai Pharmaceutical, Hainan Chang`an International Pharmaceutical |
This chapter will help you gain GLOBAL Market Analysis of Antineoplastic Agent. Further deep in this chapter, you will be able to review Global Antineoplastic Agent Market Split by various segments and Geographical Split.
Chapter 1 Global Market Analysis
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
Chapter 2 North America Market Analysis
Executive Summary North America Market (2019 vs 2024 vs 2031)
Purchase Add-Ons to Customize the Report Edition and get further granular data level data about the North America market. Add-On Cost: Request before placing the order, Respective Pricing will be informed after sending the inquiry
Qualitative Analysis for the North America Market: North America Antineoplastic Agent Market Trends North America Antineoplastic Agent Technological Road Map North America Antineoplastic Agent Market Drivers North America Antineoplastic Agent Market Restraints North America Antineoplastic Agent Market Opportunity Market Attractiveness Analysis COVID – 19 Impact Analysis PESTEL Analysis Porter’s Five Forces Analysis Product Life Cycle Industrial Chain Analysis
Chapter 3 Europe Market Analysis
Chapter 4 Asia-Pacific Market Analysis
Chapter 5 South America Market Analysis
Chapter 6 Middle East and Africa Market Analysis
Only Available with Corporate User License
Chapter 7 Top 10 Countries Analysis
Competitor's Market Share and Revenue (Subject to Data Availability for Private Players)
Chapter 8 Competitor Analysis (Subject to Data Availability (Private Players))
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Chapter 9 Qualitative Analysis (Subject to Data Availability)
Segmentation Product Analysis 2019 -2031, will provide market size split by Product. This Information is provided at Global Level, Regional Level and Top Countries Level The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 10 Market Split by Product Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 11 Market Split by Type of cancer Analysis 2019 -2031
The report with the segmentation perspective mentioned under this chapters will be delivered to you On Demand. So please let us know if you would like to receive this additional data as well. No additional cost will be applicable for the same.
Chapter 12 Market Split by End User Analysis 2019 -2031
This chapter helps you understand the Key Takeaways and Analyst Point of View of the global Antineoplastic Agent market
Chapter 13 Research Findings
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Why Chemotherapeutic Agents have a significant impact on Antineoplastic Agent market? |
What are the key factors affecting the Chemotherapeutic Agents and Biological/immunotherapeutic Agents of Antineoplastic Agent Market? |
What is the CAGR/Growth Rate of Breast Cancer during the forecast period? |
By type, which segment accounted for largest share of the global Antineoplastic Agent Market? |
Which region is expected to dominate the global Antineoplastic Agent Market within the forecast period? |
Segmentation Level Customization |
|
Global level Data Customization |
|
Region level Data Customization |
|
Country level Data Customization |
|
Company Level |
|
Additional Data Analysis |
|
Additional Qualitative Data |
|
Additional Quantitative Data |
|
Service Level Customization |
|
Report Format Alteration |
|
Published Report Editions
are Just a Tip of an Iceberg
Access the Complete Database of
Antineoplastic Agent Market
Request Sample